Clinical trials: Cephalalgia
Migraine
Migraine Survey in Gulf Region
The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks
- Trial name
- NCT06237062
- Testing
- erenumab
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Migraine
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024.
- Trial name
- NCT06532357
- Where
- United States
- Volunteers
- 1,536 people
- Sponsor
- Pfizer
Migraine
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these…
- Trial name
- PROCEED (NCT06323928)
- Testing
- Lu AG09222
- Where
- 120 sites in United States, Bulgaria and 12 more
- Volunteers
- 874 people
- Sponsor
- H. Lundbeck A/S
Migraine
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
The main goal of this trial is to learn more about the safety and tolerability of Lu AG09222 when taken together with ubrogepant.
- Trial name
- NCT06578585
- Testing
- Ubrogepant, Lu AG09222
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- H. Lundbeck A/S
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE I (NCT02828020)
- Testing
- Ubrogepant
- Where
- 90 sites in United States
- Volunteers
- 1,672 people
- Sponsor
- Allergan
Migraine, Headache
Bioequivalence Study to Compare Ibuprofen/ Paracetamol Tablets (200mg Ibuprofen/ 500mg Paracetamol) Versus Nuromol® Tablets (200mg Ibuprofen/ 500mg Paracetamol)
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Ibuprofen/ Paracetamol tablets (200mg Ibuprofen/ 500mg Paracetamol) versus Nuromol® tablets (200mg Ibuprofen/ 500mg…
- Conditions
- Migraine, Headache, Backache
- Trial name
- NCT06180070
- Testing
- Ibuprofen/ Paracetamol tablets, Nuromol® tablets
- Where
- Jordan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Migraine
Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of…
- Trial name
- NCT05399459
- Testing
- Rimegepant 25 MG, Rimegepant 75 MG
- Where
- 50 sites in Japan
- Volunteers
- 897 people
- Sponsor
- Pfizer
Migraine
Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.
- Trial name
- NCT01209741
- Testing
- telcagepant potassium, MK-0974 5Mo5C, MK-0974 12Mo5C
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain
The purpose of this study is to evaluate the effectiveness and safety of AXERT when treating a migraine at the onset of headache pain, as compared to treating a migraine only after the headache pain has reached at least moderate…
- Trial name
- NCT00212823
- Testing
- almotriptan malate
- Volunteers
- 1,450 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Pain, Headache
An Intervention to Improve Adolescent Headache Self-management
The purpose of this study is to test the efficacy of a new app to help adolescents with chronic or reoccurring headaches self manage pain.
- Trial name
- TH (NCT02475005)
- Testing
- pain self management app on smartphone
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Stephen F Butler, PhD
Migraine
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines.
- Trial name
- NCT05133323
- Testing
- Lu AG09222
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 237 people
- Sponsor
- H. Lundbeck A/S
Migraine
Efficacy and Safety of BGG492 in the Treatment of Migraine
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
- Trial name
- NCT00892203
- Testing
- BGG492, Sumatriptan
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Novartis
Cluster Headache
Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache
Multi-center, prospective, double-blind, randomized, sham-controlled pivotal study of non-invasive vagus nerve stimulation with the GammaCore® device for the acute treatment of cluster headache.
- Trial name
- CH (NCT01792817)
- Testing
- GammaCore
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- ElectroCore INC
Migraine Disorders
Biomarker Study in Participants With Migraine
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo.
- Trial name
- NCT02766517
- Testing
- Capsaicin
- Where
- 14 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Tension-Type Headache
Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a single qualifying Tension-Type-Headache…
- Trial name
- NCT02423408
- Testing
- TNX-201
- Where
- 10 sites in United States
- Volunteers
- 165 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Migraine, Common Migraine
A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of two doses of topiramate (100 and 200 mg daily) versus placebo and propranolol in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00236561
- Testing
- topiramate, propranolol
- Volunteers
- 786 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Migraine, Migraine Disorders
Exploring Clinical Trial Experiences of Patients With Migraine
Clinical study participation has historically been heavily biased toward specific demographics. This study will invite several participants to gather a wide range of information on clinical trial experiences for migraine…
- Trial name
- NCT05675189
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.